Zura Bio Limited financials
$4.00−2.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$75.2M | -$55.2M | -$62.6M |
| Net income | -$99.4M | -$45.4M | -$69.2M |
| Net margin | — | — | — |
| Diluted EPS | $-1.06 | $-0.60 | $-2.09 |
| EBITDA | -$75.2M | -$55.2M | -$62.6M |
| Operating cash flow | -$64.8M | -$28.1M | -$15.1M |
| Free cash flow | -$64.9M | -$28.2M | -$23.1M |
| Diluted shares | 94.2M | 75.1M | 33.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $109.4M | $176.5M | $99.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $113.9M | $179.5M | $100.8M |
| Total liabilities | $12.4M | $19.5M | $20.3M |
| Shareholders' equity | $101.5M | $148.4M | $60.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology